BridgeBio Pharma Inc.

BridgeBio Pharma, a Palo Alto‑based biopharma, targets genetic disorders with a Phase‑3 pipeline—Attruby for ATTR‑CM, low‑dose infigratinib for achondroplasia, Encaleret for ADH1, and BBP‑418 for LGMD—backed by collaborations with Alexion, Novartis and Stanford.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 725
HQ: Palo Alto

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
BBIO	BridgeBio Pharma Inc. Cap: 15.0B	EQUITY	NMS	USD	US10806X1028	Active	📈